Yang Peidong, Wang Zhitang, Peng Qingqin, Lian Weibin, Chen Debo
Department of Breast Surgery, Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou, Fujian, China.
Department of Radiation Oncology, Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou, Fujian, China.
Evol Bioinform Online. 2021 Nov 13;17:11769343211057573. doi: 10.1177/11769343211057573. eCollection 2021.
The microbiome plays diverse roles in many diseases and can potentially contribute to cancer development. Breast cancer is the most commonly diagnosed cancer in women worldwide. Thus, we investigated whether the gut microbiota differs between patients with breast carcinoma and those with benign tumors. The DNA of the fecal microbiota community was detected by Illumina sequencing and the taxonomy of 16S rRNA genes. The α-diversity and β-diversity analyses were used to determine richness and evenness of the gut microbiota. Gene function prediction of the microbiota in patients with benign and malignant carcinoma was performed using PICRUSt. There was no significant difference in the α-diversity between patients with benign and malignant tumors ( = 3.15e for the Chao index and = 3.1e for the ACE index). The microbiota composition was different between the 2 groups, although no statistical difference was observed in β-diversity. Of the 31 different genera compared between the 2 groups, level of only was significantly higher in the malignant tumor group than that in benign tumor group. The metabolic pathways of the gut microbiome in the malignant tumor group were significantly different from those in benign tumor group. Furthermore, the study establishes the distinct richness of the gut microbiome in patients with breast cancer with different clinicopathological factors, including ER, PR, Ki-67 level, Her2 status, and tumor grade. These findings suggest that the gut microbiome may be useful for the diagnosis and treatment of malignant breast carcinoma.
微生物群在许多疾病中发挥着多种作用，并可能促进癌症的发展。乳腺癌是全球女性中最常被诊断出的癌症。因此，我们研究了乳腺癌患者和良性肿瘤患者的肠道微生物群是否存在差异。通过Illumina测序和16S rRNA基因分类法检测粪便微生物群群落的DNA。使用α多样性和β多样性分析来确定肠道微生物群的丰富度和均匀度。使用PICRUSt对良性和恶性肿瘤患者的微生物群进行基因功能预测。良性和恶性肿瘤患者之间的α多样性没有显著差异（Chao指数为3.15e，ACE指数为3.1e）。两组之间的微生物群组成不同，尽管在β多样性方面未观察到统计学差异。在两组比较的31个不同属中，只有的水平在恶性肿瘤组中显著高于良性肿瘤组。恶性肿瘤组肠道微生物群的代谢途径与良性肿瘤组显著不同。此外，该研究确定了具有不同临床病理因素（包括雌激素受体、孕激素受体、Ki-67水平、人表皮生长因子受体2状态和肿瘤分级）的乳腺癌患者肠道微生物群的独特丰富度。这些发现表明，肠道微生物群可能对恶性乳腺癌的诊断和治疗有用。
